Medicina
Facultad
Essen University Hospital
Essen, AlemaniaPublicaciones en colaboración con investigadores/as de Essen University Hospital (114)
2024
-
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
European Urology
-
Diversity of kidney care referral pathways in national child health systems of 48 European countries
Frontiers in Pediatrics, Vol. 12
-
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Blood
-
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma
Clinical Genitourinary Cancer
-
Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine
The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis
Leukemia, Vol. 37, Núm. 7, pp. 1511-1520
-
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4
Haematologica, Vol. 108, Núm. 1, pp. 34-41
-
Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy
Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935
-
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Multiple Sclerosis and Related Disorders, Vol. 69
-
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
The Lancet, Vol. 402, Núm. 10395, pp. 41-53
-
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022
European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370
-
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY
eClinicalMedicine, Vol. 65
-
Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure
Journal of Hepatology, Vol. 79, Núm. 1, pp. 79-92
-
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
The Lancet, Vol. 401, Núm. 10378, pp. 733-746
-
THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT
Shock, Vol. 59, Núm. 3, pp. 21-25
-
The current clinical practice for management of post-infarction ventricular septal rupture: a European survey
European Heart Journal Open, Vol. 3, Núm. 5
2022
-
A Potential Role for Bile Acid Signaling in Celiac Disease-Associated Fatty Liver
Metabolites, Vol. 12, Núm. 2
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097